Quarterly report pursuant to Section 13 or 15(d)

Mezzanine Equity (Details Narrative)

v3.21.1
Mezzanine Equity (Details Narrative) - USD ($)
3 Months Ended
Dec. 21, 2020
Mar. 31, 2021
Mar. 31, 2020
Jan. 14, 2021
Dec. 31, 2020
Preferred stock, par value   $ 0.001     $ 0.001
Number of shares issued, values        
Securities Exchange Agreement [Member] | Medolife Rx, Inc. [Member]          
Acquisition percentage 51.00%     51.00%  
Share issued in exchange 9,000        
Series B Convertible Preferred Stock [Member]          
Preferred stock, par value   0.00001      
Preferred stock, stated value per share   $ 100      
Compensation expense   $ 1,522,198      
Series C Convertible Preferred Stock [Member]          
Preferred stock, par value   $ 0.00001      
Preferred stock, stated value per share   $ 100      
Number of shares issued, shares   1,000      
Number of shares issued, values   $ 169,133      
Series C Convertible Preferred Stock [Member] | Trillium Partners LP [Member]          
Number of shares issued, shares   500      
Series C Convertible Preferred Stock [Member] | Sagittarii Holdings, Inc.[Member]          
Number of shares issued, shares   500